Larimar Therapeutics Inc (LRMR) |
|
17.15 -0.45 (-2.56%)
|
03-03 15:13 |
|
Open: |
17.43 |
Pre. Close: |
17.6 |
|
High:
|
17.51 |
Low:
|
17.1 |
|
Volume:
|
29,272 |
Market Cap:
|
247M |
|
|
|
|
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases. The company's lead compound is CTI-1601, a Phase 1 clinical program to treat Friedreich's ataxia, a rare and progressive genetic disease. The company is headquartered in Bala Cynwyd, Pennsylvania. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
17.683 - 17.754 |
17.754 - 17.822 |
|
Low:
|
16.627 - 16.704 |
16.704 - 16.778 |
|
Close:
|
17.473 - 17.597 |
17.597 - 17.716 |
|
Technical analysis |
as of: 2021-03-03 2:54:25 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 21.58 One year: 24.00 |
| Support: |
Support1: 15.11 Support2: 12.57 |
| Resistance: |
Resistance1: 18.47 Resistance2: 20.55 |
| Pivot: |
18.17 |
| Moving Average: |
MA(5): 17.26 MA(20): 18.42
MA(100): 19.75  MA(250): 40.48 |
| MACD: |
MACD(12,26): -0.51 Signal(9): -0.42 |
| Stochastic oscillator: |
%K(14,3): 28.05 %D(3): 25.80 |
| RSI: |
RSI(14): 41.33 |
| 52-week: |
High: 185.76 Low: 9.01 Change(%): -89.9 |
| Average Vol(K): |
3-Month: 6357 10-Days: 6413 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.LRMR has closed above bottom band by 21.2%. Bollinger Bands are 26.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Mon, 01 Mar 2021
Here's Why We're Not Too Worried About Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation - Yahoo Finance
Thu, 18 Feb 2021
Larimar Therapeutics to Present at the SVB Leerink 10th Annual Global Healthcare Conference - GlobeNewswire
Tue, 16 Feb 2021
Feb 16, 2021 - Logos Global Management LP Buys Olema Pharmaceuticals inc, Nkarta Inc, Kinnate Biopharma Inc, Sells Global Blood Therapeutics Inc, Keros Therapeutics Inc, Sarepta Therapeutics Inc - GuruFocus.com
Mon, 08 Feb 2021
Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth - Simply Wall St
Fri, 13 Nov 2020
Larimar Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Tue, 10 Nov 2020
Larimar Therapeutics Reports Third Quarter 2020 Operating and Financial Results - GlobeNewswire
|
Financial Analysis |
| Growth |
NA |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
NA |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
NA |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
NA |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Underperform |
Price to Earnings: |
Underperform |
| Return on Equity: |
Underperform |
Debt to Equity: |
Neutral |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
15 |
| Shares Float (M) |
5 |
|
% Held by Insiders
|
2.88 |
|
% Held by Institutions
|
88.77 |
|
Shares Short (K)
|
202 |
|
Shares Short P. Month (K)
|
162 |
Stock Financials |
|
EPS
|
|
|
EPS Est This Year
|
|
|
EPS Est Next Year
|
|
|
Book Value (p.s.)
|
|
|
Profit Margin
|
|
|
Operating Margin
|
|
|
Return on Assets (ttm)
|
|
|
Return on Equity (ttm)
|
|
|
Qtrly Rev. Growth
|
|
|
Gross Profit (p.s.)
|
|
|
Sales Per Share
|
|
|
EBITDA (p.s.)
|
-2.242 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-40 |
|
Levered Free Cash Flow (M)
|
|
Stock Valuations |
|
PE Ratio
|
|
|
PEG Ratio
|
|
|
Price to Book value
|
|
|
Price to Sales
|
|
|
Price to Cash Flow
|
-6.53 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
